QC Technologies Inc (QCLS)

QC Technologies Inc. (NASDAQ: QCLS) is a healthcare company focused on pharmaceutical research and development. The company is clinical-stage and is working on therapeutic platforms built around several targets. Its pipeline includes Isomyosamine, a small molecule in clinical development that is intended to regulate the immunometabolic system and is being studied for autoimmune-related conditions such as sarcopenia, frailty, side effects associated with diabetes and obesity treatments, rheumatoid arthritis, and inflammatory bowel disease. QC Technologies is also developing Supera-CBD, a synthetic cannabidiol analog being evaluated for conditions including epilepsy, pain, and anxiety or depression. In addition, the company is pursuing a silicon photonic computing architecture for AI inference. The company has a strategic alliance with the DADA2 Foundation for research into DADA2, a rare inflammatory disease. Founded in 2014 and headquartered in New York, New York, the company was previously known as TNF Pharmaceuticals, Inc. before adopting its current name in September 2025.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.